Gansu Dunhuang Seed (600354.SS) traded flat 0 % during a 24 hours period ending at 07:49 PM Central Europe on Monday 26th. One Gansu Dunhuang Seed stock can currently be bought for about CNY 7.25 on popular exchanges. Current supply of Gansu Dunhuang Seed stocks is 527.4 mn. Gansu Dunhuang Seed has a current market capitalization of CNY 4 bn and approximately CNY 375.6 mn worth of Gansu Dunhuang Seed was traded on exchanges in the last 24 hours. Since last month end, Gansu Dunhuang Seed has traded -21.41 % down. Simple moving average of last 200 days is at CNY 6.88. The highest price of past 52 weeks was recorded at CNY 12.32 on 09/11/2026. 52 weeks low was at CNY 4.65 on 06/29/2026.
Here is how related stocks have performed in the past 24 hours:
Huarui (300626.SZ) traded flat 0 % and now trades at CNY 25.14. Current market capitalisation for Huarui is CNY 4.7 bn. Current price/earnings ratio for Huarui is 327.52.
Guizhou Guihang Automotive (600523.SS) traded flat 0 % and now trades at CNY 11.66. Guizhou Guihang Automotive has a market capitalisation of CNY 4.7 bn. Guizhou Guihang Automotive has a current price to earnings ratio of 22.
Citic Niya Wine (600084.SS) traded flat 0 % and now trades at CNY 4.2. Citic Niya Wine has a market capitalisation of CNY 4.7 bn.
Hangzhou Bio-sincerity Pha (301096.SZ) traded flat 0 % and now trades at CNY 46.25. Hangzhou Bio-sincerity Pha has a market capitalisation of CNY 4.7 bn. Hangzhou Bio‑Sincerity PHA has attracted attention amid broader activity in the innovative‑drug sector. Market observers noted that several domestic pharmaceutical stocks, including those in the AI‑driven drug‑development niche, experienced gains during recent trading sessions. In particular, shares linked to AI‑enabled pharmaceutical research and development were reported to have shown positive momentum, reflecting a broader trend toward integrating advanced computational techniques into drug discovery. Analysts highlighted that the company’s participation in this emerging field aligns with regulatory encouragement for AI‑assisted medical applications, suggesting potential for continued growth. The company’s performance appears to be supported by broader investor interest in biotech concepts, with investors increasingly allocating capital to firms that combine traditional pharmaceutical expertise with cutting‑edge technology. This trend points to a growing confidence in the long‑term prospects of AI‑enhanced drug development within China’s pharmaceutical landscape.
Arctech Solar L (688408.SS) traded flat 0 % and now trades at CNY 22.86. Current market capitalisation for Arctech Solar L is CNY 4.7 bn.